Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences
- 1 December 2018
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 192, 20-41
Abstract
No abstract availableKeywords
Funding Information
- Fondazione Arpa (2016_2)
- Progetti di Ricerca di Ateneo (PRA 2015_0085)
This publication has 314 references indexed in Scilit:
- The potential role of dopamine D3 receptor neurotransmission in cognitionEuropean Neuropsychopharmacology, 2013
- Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic DrugsCell, 2011
- Clozapine Reverses Phencyclidine-Induced Desynchronization of Prefrontal Cortex through a 5-HT1A Receptor-Dependent MechanismNeuropsychopharmacology, 2011
- From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for TreatmentNeuropsychopharmacology, 2011
- Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brainMolecular Psychiatry, 2011
- Teaching old receptors new tricks: biasing seven-transmembrane receptorsNature Reviews Drug Discovery, 2010
- Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease PsychosisNeuropsychopharmacology, 2009
- Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivoPsychopharmacology, 2009
- Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disordersTrends in Pharmacological Sciences, 2009
- Identification of a serotonin/glutamate receptor complex implicated in psychosisNature, 2008